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Abstract
Background: The Thai-Myanmar and Thai-Cambodia borders have been historically linked with
the emergence and spread of Plasmodium falciparum parasites resistant to antimalarial drugs. Indeed,
the areas are often described as harbouring multi-drug resistant parasites. These areas of Thailand
have experienced significant changes in antimalarial drug exposure patterns over the past decade.
This study describes the in vitro antimalarial susceptibility patterns of 95 laboratory-adapted P.
falciparum isolates, collected between 1998 and 2003,.
Methods: Ninety five P. falciparum isolates were collected from five sites in Thailand between 1998
and 2003. After laboratory adaptation to in vitro culture, the susceptibility of these parasites to a
range of established antimalarial drugs (chloroquine [CQ], mefloquine [MQ], quinine [QN] and
dihydroartemisinin [DHA]) was determined by the isotopic microtest.
Results: Mefloquine (MQ) sensitivity remained poorest in areas previously described as MQ-
resistant areas. Sensitivity to MQ of parasites from this area was significantly lower than those from
areas reported to harbour moderate (p = 0.002) of low level MQ resistance (p = 000001).
Importantly for all drugs tested, there was a considerable range in absolute parasite sensitivities.
There was a weak, but statistically positive correlation between parasite sensitivity to CQ and
sensitivity to both QN and MQ and a positive correlation between MQ and QN. In terms of
geographical distribution, parasites from the Thai-Cambodia were tended to be less sensitive to all
drugs tested compared to the Thai-Myanmar border. Parasite sensitivity to all drugs was stable
over the 6-year collection period with the exception of QN.
Conclusion: This study highlights the high degree of variability in parasite drug sensitivity in
Thailand. There were geographical differences in the pattern of resistance which might reflect
differences in drug usage in each area. In contrast to many other studies there were weak, but
statistically significant positive, correlations between sensitivity to CQ and sensitivity to MQ and
QN. Over the six years of sample collection, parasite sensitivity appears to have stabilized to these
drugs in these sites.
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Background
Malaria is still a major health problem in Thailand, espe-
cially along the Thai-Myanmar and Thai-Cambodia bor-
ders where multi-drug resistant malaria is highly prevalent
[1]. Chloroquine-resistant (CQR) parasites were first
reported in the late 1950s from Southeast-Asia and South-
America. Since those early reports CQR has spread
throughout the malaria endemic countries of the world.
The Malaria Control Programme of the Ministry of Public
Health of Thailand was established in 1963. The objective
of the control programme is to monitor the susceptibility
of Plasmodium falciparum to currently used antimalarial
drugs using both in vitro and in vivo tests with the ultimate
goal of providing effective malaria control strategies and
delaying the emergence of drug resistance [2]. Both
approaches to the sensitivity assessment have their
strengths and weaknesses [3]. The in vitro sensitivity mon-
itoring system is considered a suitable system for assessing
absolute sensitivity without the confounding influences
of host-related factors, such as host immunity and drug
pharmacokinetics. The results from in vitro tests, therefore,
provide a more objective insight into inherent drug sensi-
tivity than do in vivo tests. However, compared to the in
vivo test, there are technical requirements which make this
type of analysis operationally more difficult.
Several in vitro sensitivity test systems have been devel-
oped and applied to sensitivity monitoring of P. falci-
parum in endemic areas. These include traditional in vitro
tests based on the measurement of the effect of drugs on
the growth and development of malaria parasites, i.e., sch-
izont maturation or growth inhibition [4,5], incorpora-
tion of radiolabeled precursors [6], enzymatic activity of
parasite lactate dehydrogenase (pLDH) [7] or histidine-
rich protein II (HRP II) [8]. The in vitro sensitivity test
based on the standard micro-technique recommended by
the World Health Organization [5] using the schizont
maturation inhibition test has been applied successfully
in certain highly multi-drug resistant areas of Thailand.
However, the technique requires immediate laboratory
work at the sites, where availability of qualified personnel
is not readily available. One approach to solve this prob-
lem is to collect patient's blood samples and perform the
test at the central laboratories where qualified personnel
exist. This approach requires preservation of parasite sam-
ples at low temperature (-196°C) in a liquid nitrogen tank
and adaptation of the parasite isolates to short-term cul-
ture prior to in vitro sensitivity testing. An additional
advantage of this approach is that it allows multiple
assessment of drug susceptibility, increasing confidence in
the data collected, compared to the one-off drug sensitiv-
ity analysis afforded by the use of freshly collected iso-
lates. The main purpose of this study was to explore the in
vitro susceptibility of recently collected and adapted P. fal-
ciparum isolates to chloroquine, quinine, mefloquine and
dihydroartemisinin in order to establish the degree of var-
iability in parasite sensitivity, any geographical patterns
and the stability of parasite sensitivity over a six-year col-
lection period.
Methods
Parasite isolates
This study was carried out between 1998–2003, P. falci-
parum isolates were collected from malaria endemic areas
of Thailand (Figure 1), including the Thai-Myanmar bor-
der regions (Kanchanaburi, Tak, Ratchaburi and Ranong)
and the Thai-Cambodia border (Chantaburi). Approval of
the study protocol was obtained from the Ethics Commit-
tee of the Ministry of Public Health, Thailand. Fresh iso-
lates of P. falciparum were collected from patients with
acute uncomplicated falciparum malaria who presented
at Mae Sot General Hospital and Malaria Clinics located
in the various provinces. Inclusion criteria included those
who had no previous history of antimalarial treatment
within the preceding one month and with an asexual par-
asitaemia between 1,000 and 80,000/µl. All gave
informed consent for study participation. Three to five
millilitres of blood were collected into EDTA tubes from
patients with a confirmed diagnosis of uncomplicated P.
falciparum  malaria. The fresh blood samples were then
centrifuged to remove the buffy coat and cryopreserved in
liquid nitrogen following the method of Rowe [9] before
being transported to the laboratory.
Parasites were maintained in in vitro culture using the
method of Trager and Jensen [10]. Briefly, infected blood
samples were removed from liquid nitrogen tank storage
and thawed in a 37°C water bath. An equal volume of
sterile 3.5% sodium chloride was added, and the mixture
was centrifuged at 1000 × g for 5 min. The pellet was
washed three times and re-suspended with RPMI-1640
medium supplemented with 20% human serum and
placed in a 25 ml tissue culture flask in a total volume of
10 ml containing a 5% RBC suspension. The flask was
flushed with a gas mixture of 5%CO2, 5% O2 and 90% N2
and incubated at 37°C. The culture medium was changed
once a day; group O red blood cells were added to main-
tain the 5% cell suspension. Parasite growth was moni-
tored by Giemsa-stained (2% v/v, pH 6.8, 30 min) thin
smear examination.
In vitro sensitivity tests of P. falciparum isolates
Drug testing was performed using the cultured parasites
once the parasitaemia of the culture reached an optimum
density (0.5%–1% parasitaemia and 1.5% haematocrit).
In vitro susceptibility was tested by monitoring [3H]
hypoxanthine uptake [6]. Each drug was prepared as 10
mM stock solution and further diluted in RPMI-1640
medium to the desired concentrations. The plates (96-
wells microtitre plates) were dosed with antimalarialMalaria Journal 2005, 4:37 http://www.malariajournal.com/content/4/1/37
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drugs at a total of eight final concentrations as follows:
mefloquine (1, 5, 10, 25, 50, 100, 150, 200 nM), chloro-
quine (5, 10, 25, 50, 100, 150, 250, 500 nM), quinine (10,
25, 50, 100, 150, 250, 500, 1,000 nM), and dihydroartem-
isinin (0.1, 0.2, 0.4, 0.8, 1.0, 5.0, 7.5, 10.0 nM). Ten
microlitres of blood (1% parasitaemia, 20% haematocrit)
was dispensed into each well of the sterile plates, followed
by 100 µl of drug solution in RPMI-1640 without [3H]
hypoxanthine. The plates were incubated at 37°C in a
candle jar for 24 hours, pulsed with 5 µl of [3H] hypoxan-
thine solution (0.1 mCi/ml), and reincubated for an addi-
tional 24 hours. The plates were harvested using a Tomtec
March III M semi-automatic harvester, using Wallac A
Printed Filtermats (Finland), dried, and mixed with 5 ml
of scintillation fluid. Each filter mat was then placed in a
cassette and the radioactivity were measured using a 1450
MicroBeta Trilux liquid scintillation and luminescence
counter (Wallac, Finland). The drug concentration that
inhibited 50% parasite growth (IC50) were determined.
Reported data represent the mean results from at least
three independent drug sensitivity tests.
Statistical analysis
The in vitro activity of antimalarials is presented as the geo-
metric mean of the IC50s for all isolates. The Mann-Whit-
ney U-test was used to determine whether the observed
differences in the in vitro response of geographically dis-
tinct parasites to antimalarial drugs were significantly dif-
ferent. The potential for in vitro cross-resistance was
evaluated by standard linear regression analysis. For all
statistical tests the significance level (p) was set at 0.05.
Results
In vitro susceptibility of P. falciparum to antimalarials
A total of 95 P. falciparum isolates were collected from five
malaria endemic areas of Thailand: Mae-sot District, Tak
(27), Ratchaburi (1), Kanchanaburi (37), Ranong (16)
and Chantaburi Province (14). The in vitro susceptibility
data are shown in Figure 2A to 2C. The geometric mean
50% inhibitory concentration (IC50) and 95%CI were
74.3 (45.2–122.2), 162.9 (91.9–288.8), 22.2 (10.8–45.6)
and 1.35 (0.73–2.47) nM for CQ, QN, MQ and DHA
respectively. There were no major differences in drug sus-
ceptibility over the six years the samples were collected
with the exception of quinine sensitivity, which was lower
in the isolates collected in 2003 (Table 1).
In vitro susceptibility and geographical distribution
The malarious areas of Thailand have been categorized by
the clinical level of mefloquine sensitivity i.e. high level
MQ resistance (cure rate of MQ 750 mg is less than 50%;
Tak and Chantaburi provinces), moderate level MQ resist-
ance (cure rate between 50% and 70%; Kanchanaburi and
Ratchaburi provinces) and low level MQ resistance (cure
rate more than 70%; Ranong province). These groupings
were maintained in the isolates studied here in vitro. Inter-
estingly, parasites from the least MQ resistant area tended
to demonstrate highest susceptibility to the other drugs
tested.
In vitro cross-resistance
In contrast to previous studies conducted on African and
Thai isolates [11,12], there was a significant positive cor-
relation between the in vitro susceptibility to CQ and sus-
ceptibility to MQ (n = 91, Pearson r = 0.075, p = 0.010)
and QN (n = 93, Pearson r = 0.134, p < 0.0001) (Figure 3).
Similarly there was a significant positive correlations
Map of Thailand showing the sampling sites: Tak, Kan- chanaburi, Ratchaburi, Ranong and Chantaburi provinces Figure 1
Map of Thailand showing the sampling sites: Tak, Kan-
chanaburi, Ratchaburi, Ranong and Chantaburi provinces.Malaria Journal 2005, 4:37 http://www.malariajournal.com/content/4/1/37
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The scatter plot between the IC50 (nM) and the mefloquine resistance areas and the border regions Figure 2
The scatter plot between the IC50 (nM) and the mefloquine resistance areas and the border regions. A represents the chloro-
quine data, B the quinine data and C the mefloquine data. (a) is the geometric mean 50% inhibitory concentration in vitro with 
the 95% CI and (b) is the median.Malaria Journal 2005, 4:37 http://www.malariajournal.com/content/4/1/37
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between IC50 values of QN and the IC50 values of MQ (n =
91, Pearson r = 0.230, p < 0.0001). The strong correlation
between the activities of MQ and QN was not surprising
given the structural similarities between these two drugs
and has been noticed by several authors [13,14]. In con-
trast, susceptibility to DHA did not correlate with suscep-
tibility to any of the other drugs tested (data not shown).
Discussion
In response to concerns about the malaria situation in
Thailand, the government established the Malaria Control
Programme since 1963. This programme has monitored
and modified Thai policy on malaria control which was
last revised in 1995. The major aim of the programme is
to monitor the evolution of drug resistant malaria para-
sites [2]. The ability to implement a quick and relatively
cheap assay to predict drug susceptibility of P. falciparum
infections is vitally important, so that the spread of drug
resistant parasites can be monitored and controlled. The
first report of CQ resistance came from Thailand's borders
in the late 1950s. More recently, MQ resistance was shown
to develop rapidly after its introduction into clinical prac-
tice. This problem has been remedied by the introduction
and deployment of the artemisinins in combination with
MQ. Experience with CQ has highlighted the utility of
drug sensitivity assays in plotting the emergence and
spread of resistance. More recently molecular tools have
found utility. For example the use of the K76T mutation
in pfcrt gene as a marker for CQ susceptibility is the most
useful molecular marker for CQ resistance, however,
some parasite isolates that are sensitive to CQ also carried
this mutation [11,15] and the use of this strategy is based
on a full knowledge of all potential resistance mutations.
Furthermore, the large variability in parasite sensitivity to
drugs such as CQ suggests that although one molecular
event may be the dominant control of susceptibility, other
molecular events must contribute to this variability [16].
There have been many studies looking at parasite chemo-
sensitivity in S.E.Asia. In general, the pattern of sensitivity
shows consistency across the region, although parasite
responses in parasites from Vietnam tend to show better
responses to drugs [17,18]. Decreased susceptibility to
quinine was first reported at the beginning of the 1980s in
patients living near the Thai-Cambodia border [19,20].
The data reported in this current study indicate that the P.
falciparum  susceptibility to QN is stable or may have
slightly improved recently. With respect to the other drugs
studied against parasite sensitivity apperas to have
stabilized.
Several studies have reported evidence of cross-resistance
among certain group of quinoline-containing antimalar-
ial drugs, i.e., QN, MQ and HF, while showing an inverse
relationship between this group of drugs and sensitivity to
CQ [14,21-24]. Similarly, in other studies, the sensitivity
of P. falciparum field isolates to the two structurally related
drugs QN and MQ was strongly correlated [13,14,25].
This pattern of cross-resistance was also confirmed in this
study. In contrast, a weak, but statistically significant, pos-
itive correlation was observed between sensitivity to CQ
and sensitivity to either MQ or QN. The mechanisms
behind this observation remains to be determined, but it
does suggest that additional factors must be operational
in these parasites compared to those displaying a clear
negative correlation in their susceptibility patterns.
Although a number of reports showed a positive correla-
tion between in vitro susceptibilities of DHA and quino-
lines such as mefloquine and quinine, this cross-
resistance was not apparent in this study [11,12,25]. In
terms of distribution within Thailand, parasites from the
Thai-Cambodia tended to be more resistant to all drugs
evaluated compared to parasites from the Thai-Myanmar
border.
The in vitro sensitivity data from adapted parasites showed
the clearer view of drug profiles, which allows multiple
assessment of drug testing. The drug profile in this study
showed that the pattern of MQ resistance was spread to
most of endemic areas, especially along the borders. The
old drug policy was based on the level of MQ resistance
areas, which treated the falciparum malaria with single
dose of MQ 750 mg in low MQ resistance area, whereas
the moderate and high MQ resistance areas were treated
Table 1: In vitro susceptibility of Thai P. falciparum isolates according the years
Year GMIC50 CQ (nM) GMIC50 QN (nM) GMIC50 MQ (nM) GMIC50 DHA (nM)
Mean 95%CI Mean 95%CI Mean 95%CI Mean 95%CI
1998 72.5 56.7–89.7 178.3 121.1–262.4 20.1 11.7–34.5 1.07 0.82–1.39
2000 65.1 44.8–94.5 243.4 163.7–361.8 28.1 15.8–50.1 1.64 0.92–2.92
2002 67.8 53.2–86.5 184.7 152.1–224.5 30.4 25.5–36.1 1.46 1.16–1.84
2003 79.1 68.8–90.1 136b 115.2–160.4 19.1 15.3–23.7 1.35 1.12–1.63
a Geometric mean 50% inhibitory concentration in vitro
b Significant difference with 2000 (p = 0.012) and 2002 (p = 0.024)Malaria Journal 2005, 4:37 http://www.malariajournal.com/content/4/1/37
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with multiple dose of MQ 750 mg plus 300 mg and 500
mg of artesunate at 6-hour interval, respectively [2]. From
the fact of increasing the MQ resistance, the malaria con-
trol policy has been revised, which aim to reduce the MQ
resistance. Thus, the combination of artemisinin deriva-
tives with MQ has been introduced as first line drug for
treating non-severe falciparum malaria throughout the
country. However, QN still remains the first line drug for
severe malaria treatment [26].
Conclusion
This study indicates a relative stability in parasite suscep-
tibility to four key drugs in the border areas of Thailand.
Notably, resistance to CQ and MQ remains at a high level
although there is substantial variation. There are indica-
tions that QN sensitivity may have increased slightly and,
importantly for combination chemotherapy, parasite sus-
ceptibility to the artemisinin derivative, DHA remains
high. This supports the decision of the Thai malaria con-
trol programme to introduce artemisinin containing MQ
combinations as first line malaria treatment for the
country.
Acknowledgements
This work was supported by Thailand Research Fund for the scholarship of 
The Royal Golden Jubilee (RGJ) Ph.D. programme to W.C. M.M. and K.N. 
were supported by Thailand-Tropical Disease Research Programme (ID 02-
2-MAL-24-047). We would like to thank Malaria Research Unit, Chulalong-
korn University, Thailand for parasites isolates.
References
1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR:
Epidemiology of drug-resistant malaria.  Lancet Infect Dis 2002,
2:209-218.
2. Malaria-Division: Malaria Control Programme in Thailand Malaria Divi-
sion, Department of Communicable Disease Control (CDC) of the
Ministry of Public Health, Thailand; 1998. 
3. World Health Organization: Chemotherapy of Malaria and
Resistance in Plasmodium falciparum: What next?  Trends
Parasitol 2001, 17:582-588.
4. Rieckmann KH, Campbell GH, Sax LJ, Mrema JE: Drug sensitivity of
Plasmodium falciparum. An in-vitro  microtechnique.  Lancet
1978, i:22-23.
5. World Health Organization: In vitro microtest (MARK II) for the
assessment of the response of Plasmodium falciparum to chlo-
roquine, mefloquine, quinine, sulfadoxine/pyrimentamine
and amodiaquine.  World Health Organization: Geneva,
Switzerland; 1990. 
6. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD: Quantitative
assessment of antimalarial activity in vitro by a semiauto-
mated microdilution technique.  Antimicrob Agents Chemother
1979, 16:710-718.
7. Makler MT, Hinrichs DJ: Measurement of the lactate dehydro-
genase activity of Plasmodium falciparum as an assessment of
parasitemia.  Am J Trop Med Hyg 1993, 48:205-210.
8. Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C: Histi-
dine-rich protein II: a novel approach to malaria drug sensi-
tivity testing.  Antimicrob Agents Chemother 2002, 46:1658-1664.
9. Rowe AW, Eyster E, Kellner A: Liquid nitrogen preservation of
red blood cells for transfusion; a low glycerol-rapid freeze
procedure.  Cryobiology 1968, 5:119-128.
10. Trager W, Jensen JB: Human malaria parasites in continuous
culture.  Science 1976, 193:673-675.
11. Ringwald P, Bickii J, Basco LK: In vitro activity of dihydroartem-
isinin against clinical isolates of Plasmodium falciparum in
Yaounde, Cameroon.  Am J Trop Med Hyg 1999, 61:187-192.
12. Brockman A, Price RN, Van Vugt M, Heppner DG, Walsh D, Sookto
P, Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F: Plas-
modium falciparum antimalarial drug susceptibility on the
northwestern border of Thailand during five years of exten-
sive use of artesunate-mefloquine.  Trans R Soc Trop Med Hyg
2000, 94:537-544.
13. Wongsrichanalai C, Wimonwattratee T, Sookto P, Laoboonchai A,
heppner DG, Kyle DE, Wernsdorfer WH: In vitro sensitivity of
The scatter diagram and the regression line representing the  relationship between IC50 (nM) values of CQ, QN and MQ Figure 3
The scatter diagram and the regression line representing the 
relationship between IC50 (nM) values of CQ, QN and MQ.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2005, 4:37 http://www.malariajournal.com/content/4/1/37
Page 7 of 7
(page number not for citation purposes)
Plasmodium falciparum to artesunate in Thailand.  Bull World
Health Organ 1999, 77:392-398.
14. Suebsaeng L, Wernsdorfer WH, Rooney M: Sensitivity to quinine
and mefloquine of Plasmodium falciparum in Thailand.  Bull
World Health Organ 1986, 64:759-765.
15. Labbe AC, Patel S, Crandall I, Kain KC: Molecular surveillance sys-
tem for global patterns of drug resistance in imported
malaria.  Emerg Infec Dis 2003, 9:33-36.
16. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, Subramanian G,
Aravind L, Cooper RA, Wootton JC, Xiong M, Su XZ: Multiple
transporters associated with malaria parasite responses to
chloroquine and quinine.  Mol Microbiol 2003, 49:977-989.
17. Singhasivanon P: Mekong Malaria. Malaria, multi-drug resist-
ance and economic development in the greater Mekong sub-
region of Southeast Asia.  Southeast Asian J Trop Med Public Health
1999, 30:1-101.
18. Huong NM, Hewitt S, Davis TME, Dao Le D, Toan TQ, Kim TB, Hanh
NT, Phuong VN, Nahn DH, Cong Le D: Resistance of Plasmodium
falciparum to antimalarial drugs in a highly endemic area of
southern Viet Nam: a study in vivo and in vitro.  Trans R Soc Trop
Med Hyg 2001, 95:325-329.
19. Giboda M, Desnis MB: Response of Kampucheam strains of
Plasmodium falciparum to antimalarials: in vivo assessment of
quinine and quinine plus tetracycline; multiple drug resist-
ance in vitro.  J Trop Med Hyg 1988, 91:205-211.
20. Denis MB, Kouznetsov RL, Gibboda M: In vivo response of multi-
resistant Plasmodium falciparum infections to mefloquine and
its combination with sulfadoxine/pyrimethamine in
Cambodia.  Folia Parasitol 1991, 38:187-188.
21. Cowman AF, Galatis d, Thompson JK: Selection for mefloquine
resistance in Plasmodium falciparum is linked to amplification
of the pfmdr1 gene and cross-resistance to halofantrine and
quinine.  Proc Natl Acad Sci U S A 1994, 91:1143-1147.
22. Peel SA, Bright P, Yount B, Handy J, Baric RS: A strong association
between mefloquine and halofantrine resistance and ampli-
fication, overexpression, and mutation in the P-glycoprotein
gene homolog (pfmdr) of Plasmodium falciparum in vitro.  Am J
Trop Med Hyg 1994, 51:648-658.
23. Webster HK, Boudreau EF, Payanand K, Yongvanitchit K, Pang LW:
Antimalarial drug susceptibility testing of Plasmodium falci-
parum  in Thailand using a microdilution radioisotope
method.  Am J Trop Med Hyg 1985, 34:228-235.
24. Wilson CM, Volkman SK, Thaithong S, Martin SK, Kyle DE, Milhous
WK, Wirth DF: Amplification of pfmdr1 associated with meflo-
quine and halofantrine resistance in Plasmodium falciparum
from Thailand.  Mol Biochem Parasitol 1993, 57:151-160.
25. Lim P, Chim P, Sem R, Nemh S, Poravuth Y, Lim C, Seila S, Tsuyuoka
R, Denis MB, Socheat D, Fandeur T: In vitro monitoring of Plasmo-
dium falciparum susceptibility to artesunate, mefloquine, qui-
nine and chloroquine in Cambodia: 2001–2002.  Acta Trop
2005, 93:31-40.
26. Malaria Division: Guideline for the treatment of uncomplicated falciparum
malaria Malaria Division, Department of Communicable Disease Con-
trol (CDC) of the Ministry of Public Health, Thailand; 2004. 